Participated · Series C · Jun 2021

Insilico Medicine develops Pharma.AI, a generative AI platform that spans biology, generative chemistry, clinical medicine and research and integrates LLM-powered engines such as Nach01 and Dora. The company operates Life Star1, a fully robotic lab that includes a bipedal humanoid AI Scientist to automate and optimize research workflows. Insilico has built a wholly-owned discovery portfolio of 30 assets, with 10 assets having received IND clearance, and its lead candidate Rentosertib has completed a Phase IIa trial showing favorable safety and a dose-dependent FVC response. The company reports it can nominate preclinical candidates in 12–18 months and synthesize/test 60–200 molecules per program, reflecting accelerated early-stage discovery. Insilico also generates sustainable revenue through out-licensing agreements (collectively valued at over $2.1 billion) and collaborations (collected value over $1.4 billion), with milestone payments contributing to financial performance. Future plans announced include refining AI models and algorithms, expanding and updating its automated lab, advancing clinical validation of its flagship IPF candidate, and accelerating other in-house and co-developed pipelines. Insilico Medicine is a clinical-stage, end-to-end AI-driven drug discovery company led by founder and CEO Alex Zhavoronkov. The company develops AI platforms that connect biology, chemistry, and clinical-trials analysis using deep generative models, reinforcement learning, transformers, and other machine-learning techniques. Its platforms are used to discover novel targets and design molecular structures with desired properties across oncology, fibrosis, immunity, central nervous system, and aging-related diseases. Insilico says it will use the new funding to accelerate its internal programs and to apply its platform to uncover more novel therapeutics. The company recently announced promising preclinical candidates for COVID-19 (and related variants) and for ALS. Insilico is headquartered in Hong Kong and sources R&D and management resources across the USA, Belgium, Russia, the UK, Taiwan, and China. Insilico Medicine builds an AI-driven drug discovery platform that identifies new targets and molecules and also develops its own therapeutics across fibrosis, immunology, oncology and CNS. The company began as a discovery-focused business and, since 2019, has been advancing in-house drug programs, nominating eight preclinical candidates since 2021. It generates revenue from R&D collaborations (including upfronts and milestones) and customer subscriptions to its platform. Insilico is in the R&D stage, is not yet profitable, and employs about 200 people across six countries and regions. The firm plans to use new capital to fund Phase I studies, further develop its AI platform, and pursue global expansion and strategic initiatives such as a robotic drug discovery laboratory and a robotic biological data factory. A prototype robotic lab is planned for Suzhou and will include AGVs and a phenotyping partnership with X-Imaging. Insilico Medicine operates AI platforms (PandaOmics for target discovery and Chemistry42 for molecule design) to accelerate drug discovery and reduce guesswork in target-to-molecule development. The company demonstrated a proof-of-concept by identifying a novel target for idiopathic pulmonary fibrosis and designing a candidate that progressed through animal studies. That IPF project condensed preclinical development to about 18 months at a cost of roughly $2.6 million, and Insilico says it has 16 therapeutic assets across programs. The company is filing an investigational new drug (IND) application with the FDA, plans to begin human dosing this year, and aims to start a clinical trial late this year or early next year. Insilico has collaborated with Pfizer, Johnson & Johnson, Taisho Pharmaceuticals, and announced a new partnership with Teva to use PandaOmics. Insilico Medicine is a Hong Kong-based developer of next-generation AI for drug discovery that applies deep learning across the drug discovery and development process. Its core technologies include generative chemistry and target-identification platforms, and the company collaborates with biopharmaceutical firms using disease-relevant assays to validate solutions and generate machine-learnable data. Insilico has identified promising targets across cancer, fibrosis, NASH, immunology and CNS. The company completed a $37M Series B financing to support commercialization and pipeline advancement. It plans to use the funds to commercialize its validated generative chemistry and target-identification technology, build a senior management team with pharmaceutical experience, and further develop and partner on specific therapeutic programs.

Participated · Series D · Jun 2021

HiFiBiO Therapeutics is a multinational biotherapeutics company that combines single-cell profiling, deep biological expertise, and data intelligence (DIS™) to discover and develop antibody drugs. Its core focus is differentiated antibody therapeutics for oncology and autoimmune disorders, with multiple discovery-stage programs and clinical candidates. The company will use proceeds from its oversubscribed $75M Series D to advance two lead oncology antibodies—HFB200301 (anti‑TNFR2) and HFB301001 (second‑generation anti‑OX40)—into Phase I trials and to continue discovery and clinical development. HiFiBiO also highlighted prior progress including rapid development of HFB30132A, a SARS‑CoV‑2 neutralizing antibody, into a Phase I trial (NCT04590430) and the launch of IND‑enabling studies and biomanufacturing for multiple antibodies. The company intends to validate its DIS™ approach and biomarker hypotheses in the clinic to enhance the probability of trial success for current and future programs. HiFiBiO operates laboratories across Cambridge, Mass.; Paris; Shanghai; Hong Kong; and Hangzhou, reflecting a global footprint. HiFiBiO Therapeutics operates a proprietary single-cell analytics platform (including CelliGO™) and Drug Intelligent Science (DIS™) to enable deep immune profiling and antibody discovery. The company integrates biological expertise with comprehensive single-cell technologies to identify precise patient subsets and novel biomarkers. HiFiBiO aims to advance multiple antibody drug candidates into clinical trials and accelerate pipeline development. It plans to use platform expansion to increase discovery throughput while reducing time and costs. The company has announced collaborations, an acquisition, a joint venture, and a Nature Genetics publication that demonstrate scientific and strategic progress. HiFiBiO maintains laboratories across Cambridge, Mass., Paris, France, and Shanghai, China. HiFiBiO Therapeutics develops antibody drugs by integrating deep biological expertise with single-cell profiling technologies and its proprietary single-B-cell functional antibody discovery CelliGOTM platform. The company is focused on advancing a pipeline of antibody therapeutics for cancer and autoimmune diseases and is establishing strategic partnerships with pharmaceutical and biotechnology companies to drive that pipeline. HiFiBiO operates more than 50 full-time employees across three facilities in the USA, France and China, with laboratories in Cambridge, MA and Hangzhou, China located within Nest.Bio Ventures incubator facilities. Liang Schweizer, PhD, serves as President and CEO, supported by a leadership team including Jeff He (COO), Colin Brenan, PhD (CCO) and Fred Dom (CFO). Financially, the company completed a $37.5M Series B financing in 2018 to support its discovery and development efforts. The company positions its proprietary platform and strategic partnerships as central to advancing its therapeutic pipeline.

Led · Equity · Nov 2019

Sungiven Foods is a Chinese fresh-produce retailer. The company participates in China’s fresh produce market. Maison Capital invested $20 million in Sungiven Foods, the PE firm said in a statement on its WeChat official account. The article provides no details on the company’s products beyond fresh produce. No operating metrics, revenue figures, or future plans were disclosed in the piece. The announcement was reported as part of a China Deal Monitor update.

Led · Series A · Apr 2019

Boomplay is a music streaming service that offers a freemium model where users can stream for free with advertisements and certain limitations, and a paid subscription that adds offline play and ad-free listening. As of February 2019 the company had acquired over 42 million users and hosts the largest online African music catalogue with 5 million tracks. The app is available on Android, iOS and web and the company operates four teams across Nigeria, Ghana, Kenya and Tanzania covering major West and East African markets. Now a wholly-owned subsidiary of the joint venture between Transsion Holdings and NetEase, Boomplay plans to use new funding to accelerate expansion. Planned uses include content acquisition, product optimization, recruitment, and further consolidation of its position as the leader in the African market. The company is led by CEO Joe He.

Participated · Series A · Jun 2016

uSens is an augmented reality and virtual reality developer that builds hand and head position tracking technologies enabling naturally interactive AR/VR experiences without wired controllers or peripherals. The company leverages machine learning and computer vision techniques to deliver its tracking solutions. It was founded in 2013 by Anli He (CEO) and Yue Fei (CTO) and is based in San Jose, California. uSens raised $20M in a Series A to support product development. The company intends to use the funds to launch in 2016 its 26DOF hand-tracking and 6DOF head-tracking tools. Returning investor Maison Capital and several new investors joined the financing, indicating existing support and new strategic backers. uSens, Inc. is a San Jose, California–based provider of full 3D interactive solutions for virtual reality and augmented reality. The company offers 3D gesture recognition on mobile platforms that combines virtual and augmented reality and targets applications beyond gaming, such as education, healthcare, entertainment and business training. Its product lineup includes the Impression Pi mobile VR+AR headset with gesture control and 6DOF head position tracking, and the Fingo Virtual Touch (FVT) touch-free 3D interactive kiosks in China. Co-founded in 2013 by Anli He (CEO), Dr. Yue Fei (CTO) and Dr. Chris Shi, uSens focuses on computer vision and 3D interactive solutions. The company completed a $5.5M pre-Series A financing and plans to use the funds to expand R&D in computer vision and 3D interactive solutions, further product development, and business development in the United States and China.